Association between the indole pathway of tryptophan metabolism and subclinical depressive symptoms in obesity: a preliminary study.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
23
03
2021
accepted:
29
11
2021
revised:
24
11
2021
pubmed:
11
1
2022
medline:
26
4
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Converging data support the role of chronic low-grade inflammation in depressive symptomatology in obesity. One mechanism likely to be involved relies on the effects of inflammation on tryptophan (TRP) metabolism. While recent data document alterations in the indole pathway of TRP metabolism in obesity, the relevance of this mechanism to obesity-related depressive symptoms has not been investigated. The aim of this preliminary study was to assess the association between plasma levels of TRP and indole metabolites and depressive symptoms in 44 subjects with severe or morbid obesity, free of clinically relevant neuropsychiatric disorders. The interaction effect of inflammation, reflected in serum high-sensitive C-reactive protein (hsCRP) levels, and indoles on depressive symptoms was also determined. Higher serum levels of hsCRP and lower concentrations of TRP and indoles, particularly indole-3-carboxaldehyde (IAld), correlated with more severe depressive symptoms. Interestingly, the effect of high hsCRP levels in predicting greater depressive symptoms was potentiated by low IAld levels. These results comfort the link between inflammation, the indole pathway of TRP metabolism, and obesity-related depressive symptoms.
Identifiants
pubmed: 35001078
doi: 10.1038/s41366-021-01049-0
pii: 10.1038/s41366-021-01049-0
doi:
Substances chimiques
Indoles
0
Kynurenine
343-65-7
indole
8724FJW4M5
Tryptophan
8DUH1N11BX
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
885-888Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Capuron L, Lasselin J, Castanon N. Role of adiposity-driven inflammation in depressive morbidity. Neuropsychopharmacology. 2017;42:1–14. https://doi.org/10.1038/npp.2016.123.
doi: 10.1038/npp.2016.123.
Delgado I, Huet L, Dexpert S, Beau C, Forestier D, Ledaguenel P, et al. Depressive symptoms in obesity: Relative contribution of low-grade inflammation and metabolic health. Psychoneuroendocrinology. 2018;91:55–61. https://doi.org/10.1016/j.psyneuen.2018.02.030.
doi: 10.1016/j.psyneuen.2018.02.030.
pubmed: 29525586
Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130:226–38. https://doi.org/10.1016/j.pharmthera.2011.01.014.
doi: 10.1016/j.pharmthera.2011.01.014.
pubmed: 21334376
pmcid: 3072299
Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31. https://doi.org/10.1016/j.it.2005.11.006.
doi: 10.1016/j.it.2005.11.006.
pubmed: 16316783
Wang Q, Liu D, Song P, Zou MH. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci (Landmark Ed). 2015;20:1116–43. https://doi.org/10.2741/4363.
doi: 10.2741/4363.
Hunt C, Macedo E, Cordeiro T, Suchting R, de Dios C, Cuellar Leal VA, et al. Effect of immune activation on the kynurenine pathway and depression symptoms – a systematic review and meta-analysis. Neurosci Biobehav Rev. 2020;118:514–23. https://doi.org/10.1016/j.neubiorev.2020.08.010.
doi: 10.1016/j.neubiorev.2020.08.010.
pubmed: 32853625
pmcid: 8087452
O’Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009;14:511–22. https://doi.org/10.1038/sj.mp.4002148.
doi: 10.1038/sj.mp.4002148.
pubmed: 18195714
Cussotto S, Delgado I, Anesi A, Dexpert S, Aubert A, Beau C, et al. Tryptophan metabolic pathways are altered in obesity and are associated with systemic inflammation. Front Immunol. 2020;11:1–7. https://doi.org/10.3389/fimmu.2020.00557.
doi: 10.3389/fimmu.2020.00557.
Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun. 2018;9:1–10. https://doi.org/10.1038/s41467-018-05470-4.
doi: 10.1038/s41467-018-05470-4.
Zelante T, Puccetti M, Giovagnoli S, Romani L. Regulation of host physiology and immunity by microbial indole-3-aldehyde. Curr Opin Immunol. 2021;70:27–32. https://doi.org/10.1016/j.coi.2020.12.004.
doi: 10.1016/j.coi.2020.12.004.
pubmed: 33454521
Zhang LS, Davies SS. Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med. 2016;8:46. https://doi.org/10.1186/s13073-016-0296-x .
Arnoriaga-Rodríguez M, Mayneris-Perxachs J, Burokas A, Contreras-Rodríguez O, Blasco G, Coll C, et al. Obesity impairs short-term and working memory through gut microbial metabolism of aromatic amino acids. Cell Metab. 2020;32:548–560.e7. https://doi.org/10.1016/j.cmet.2020.09.002.
doi: 10.1016/j.cmet.2020.09.002.
pubmed: 33027674
Liu Z, Dai X, Zhang H, Shi R, Hui Y, Jin X, et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat Commun. 2020;11:1–14. https://doi.org/10.1038/s41467-020-14676-4.
doi: 10.1038/s41467-020-14676-4.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33. https://doi.org/10.1016/S0924-9338(99)80239-9.
doi: 10.1016/S0924-9338(99)80239-9.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9. https://doi.org/10.1192/bjp.134.4.382.
doi: 10.1192/bjp.134.4.382.
pubmed: 444788
Anesi A, Rubert J, Oluwagbemigun K, Orozco-Ruiz X, Nöthlings U, Breteler MMB, et al. Metabolic profiling of human plasma and urine, targeting tryptophan, tyrosine and branched chain amino acid pathways. Metabolites. 2019;9:261. https://doi.org/10.3390/metabo9110261 .
Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7:468–73. https://doi.org/10.1038/sj.mp.4000995.
doi: 10.1038/sj.mp.4000995.
pubmed: 12082564
Abildgaard A, Elfving B, Hokland M, Wegener G, Lund S. Probiotic treatment reduces depressive-like behaviour in rats independently of diet. Psychoneuroendocrinology. 2017;79:40–8. https://doi.org/10.1016/j.psyneuen.2017.02.014.
doi: 10.1016/j.psyneuen.2017.02.014.
pubmed: 28259042
Ye L, Bae M, Cassilly CD, Jabba SV, Thorpe DW, Martin AM, et al. Enteroendocrine cells sense bacterial tryptophan catabolites to activate enteric and vagal neuronal pathways. Cell Host Microbe. 2021;29:179–196.e9. https://doi.org/10.1016/j.chom.2020.11.011 .
Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Jessica E, Mayo L, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and CNS inflammation via the aryl hydrocarbon receptor. Nat Med. 2016;22:586–97. https://doi.org/10.1038/nm.4106.
doi: 10.1038/nm.4106.
pubmed: 27158906
pmcid: 4899206